

# Ferozsons Laboratories Limited

## Condensed Interim Unconsolidated Statement of Profit or Loss (Un-audited)

For the half year and quarter ended 31 December 2020

	Half year ended		Quarter ended	
	31 December 2020	31 December 2019	31 December 2020	31 December 2019
	Rupees		Rupees	
Revenue - net	<b>2,840,456,991</b>	2,523,155,152	<b>1,551,748,648</b>	1,334,327,324
Cost of sales	<b>(1,599,903,719)</b>	(1,408,996,902)	<b>(883,942,426)</b>	(732,498,652)
<b>Gross profit</b>	<b>1,240,553,272</b>	1,114,158,250	<b>667,806,222</b>	601,828,672
Administrative expenses	<b>(192,626,962)</b>	(185,299,271)	<b>(92,636,795)</b>	(92,484,589)
Selling and distribution expenses	<b>(654,647,182)</b>	(723,005,004)	<b>(346,136,449)</b>	(409,792,268)
Other expenses	<b>(37,284,444)</b>	(20,082,783)	<b>(23,440,323)</b>	(9,537,842)
Other income	<b>56,252,904</b>	68,205,295	<b>38,413,672</b>	33,730,212
<b>Profit from operations</b>	<b>412,247,588</b>	253,976,487	<b>244,006,327</b>	123,744,185
Finance cost	<b>(12,754,830)</b>	(11,937,037)	<b>(4,334,664)</b>	(7,589,048)
<b>Profit before taxation</b>	<b>399,492,758</b>	242,039,450	<b>239,671,663</b>	116,155,137
Taxation	<b>(110,414,151)</b>	(63,911,259)	<b>(60,916,912)</b>	(21,029,211)
<b>Profit after taxation</b>	<b>289,078,607</b>	178,128,191	<b>178,754,751</b>	95,125,926
Earnings per share - basic and diluted	<b>7.98</b>	4.92	<b>4.93</b>	2.63
		<i>Re-stated</i>		<i>Re-stated</i>

Ferozsons Laboratories Limited

Condensed Interim Consolidated Statement of Profit or Loss (Un-audited)

For the half year and quarter ended 31 December 2020

	Half year ended		Quarter ended	
	31 December 2020	31 December 2019	31 December 2020	31 December 2019
----- Rupees -----				
Revenue - net	<b>3,681,309,883</b>	2,856,850,765	<b>2,179,742,333</b>	1,519,974,235
Cost of sales	<b>(2,115,538,136)</b>	(1,739,438,268)	<b>(1,218,699,841)</b>	(928,523,198)
<b>Gross profit</b>	<b>1,565,771,747</b>	1,117,412,497	<b>961,042,492</b>	591,451,037
Administrative expenses	<b>(220,761,468)</b>	(207,971,631)	<b>(108,744,906)</b>	(105,156,023)
Selling and distribution expenses	<b>(697,361,442)</b>	(747,418,266)	<b>(377,682,918)</b>	(420,970,483)
Other expenses	<b>(60,148,356)</b>	(20,082,783)	<b>(44,084,102)</b>	(9,011,753)
Other income	<b>67,866,041</b>	86,517,254	<b>41,570,461</b>	43,336,569
<b>Profit from operations</b>	<b>655,366,522</b>	228,457,071	<b>472,101,027</b>	99,649,347
Finance costs	<b>(20,980,464)</b>	(12,614,487)	<b>(9,562,562)</b>	(7,863,301)
<b>Profit before taxation</b>	<b>634,386,058</b>	215,842,584	<b>462,538,465</b>	91,786,046
Taxation	<b>(111,958,643)</b>	(66,147,234)	<b>(58,682,626)</b>	(18,411,917)
<b>Profit after taxation</b>	<b>522,427,415</b>	149,695,350	<b>403,855,839</b>	73,374,129
<i>Attributable to:</i>				
Owners of the Company	<b>475,145,948</b>	154,875,485	<b>358,380,186</b>	77,370,094
Non-controlling interests	<b>47,281,467</b>	(5,180,135)	<b>45,475,653</b>	(3,995,965)
<b>Profit after taxation</b>	<b>522,427,415</b>	149,695,350	<b>403,855,839</b>	73,374,129
Earnings per share - basic and diluted	<b>13.12</b>	4.28	<b>9.90</b>	2.14
		<i>Re-stated</i>		<i>Re-stated</i>